BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8603458)

  • 1. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer.
    Soda H; Oka M; Fukuda M; Kinoshita A; Sakamoto A; Araki J; Fujino S; Itoh N; Watanabe K; Kanda T; Nakano M; Hara K
    Cancer Chemother Pharmacol; 1996; 38(1):9-12. PubMed ID: 8603458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.
    Takada M; Fukuoka M; Ariyoshi Y; Furuse K; Niitani H; Ota K; Motomiya M; Hasegawa K; Tominaga K; Kuriyama T
    Cancer Chemother Pharmacol; 1992; 31(3):182-6. PubMed ID: 1281446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
    Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of recombinant human granulocyte colony-stimulating factor (RHG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients].
    Shi YK; Feng FY; Sun Y
    Zhonghua Nei Ke Za Zhi; 1994 Nov; 33(11):739-42. PubMed ID: 7541325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
    Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Zhou C; Huang Y; Wang D; An C; Zhou F; Li Y; Chen G; Wu C; He J; Wu G; Song X; Gao J; Liu W; Li B; Shi J; Huang C; Yu J; Feng J; Yue H; Shi M; Xia J
    Clin Lung Cancer; 2016 Mar; 17(2):119-27. PubMed ID: 26781346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
    Xu B; Tian F; Yu J; Song Y; Shi J; Zhang B; Zhang Y; Yuan Z; Wu Q; Zhang Q; Nan K; Sun Q; Li W; Hu J; Bi J; Meng C; Dai H; Jiang H; Yue S; Cao B; Sun Y; Wang S; Tong Z; Shen P; Wu G; Tang L; Deng Y; Jia L; Shen K; Zhuang W; Xie X; Wu Y; Chen L
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):23-7. PubMed ID: 26796802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dose intensity chemotherapy in lung cancer].
    Takada M; Fukuoka M; Negoro S; Masuda N; Kudo S
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2005-12. PubMed ID: 1699498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of timing of granulocyte-colony stimulating factor administration on leukopenia induced by systemic chemotherapy in patients with non-small-cell lung cancer--multi-center randomized crossover study].
    Katakami N; Hasegawa T; Umeda B; Adachi S; Ishii N; Takada Y; Tsubota N; Nakano K; Tamura R; Nakai H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1996 May; 34(5):520-8. PubMed ID: 8753109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
    Ji X; Xu L; Pan P; Xu Z; Wang A; Li Y
    Thorac Cancer; 2022 Jan; 13(1):117-125. PubMed ID: 34791805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
    Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer.
    Eguchi K; Etou H; Miyachi S; Morinari H; Nakada K; Noda K; Ohkuni Y; Watanabe K; Yamada Y; Ohe Y
    Eur J Cancer; 1994; 30A(2):188-94. PubMed ID: 7512356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
    Shi YK; Liu P; Yang S; Han XH; He XH; Ai B; Qin Y; Li B; Huang DZ; Zhang CG; Sun Y
    Ai Zheng; 2006 Apr; 25(4):495-500. PubMed ID: 16613688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in white blood cells and myeloperoxidase activity in rhG-CSF prophylactic patients receiving cytotoxic chemotherapy.
    Charuruks N; Krailadsiri P; Voravud N; Nitipaijit N; Srisink N; Settapiboon R
    J Med Assoc Thai; 1994 Aug; 77(8):426-33. PubMed ID: 7533203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study.
    Sun XS; Wang Z; Ren SH; Zhang HL; Liu LJ; Du HB; Liu XW; Liu JF
    Thorac Cancer; 2022 Sep; 13(17):2429-2435. PubMed ID: 35859328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of combination chemotherapy with mitomycin C, vindesine and cisplatin (MVP therapy) in advanced non-small cell lung cancer].
    Setoguchi J; Sawada M; Onodera H; Sigeta M; Nakai M; Nakano K; Kanatsuna T; Kondoh M; Hotta T; Hayashi H
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2399-403. PubMed ID: 2546504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.